Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech or the Company, 6990.HK) announced that results from both ...

SCLC, addressing a high-relapse setting with limited second-line efficacy and modest survival benefit. Ifinatamab deruxtecan ...

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...

DNADX high scores predicted improved PFS, supporting genomic instability and DNA repair deficiency as biologically relevant ...

Phase 1/2 RAINFOL™-01 data showed the combination ofrinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian c ...

The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.

This antibody-drug conjugate targets a specific protein associated with poor prognosis in patients whose disease progressed after platinum-based chemotherapy.

At AACR 2026, the Genialis™ Supermodel–powered RNA survival model outperforms standard of care in real-world clinical data, establishing a scalable biomarker framework for ADC drug developmentBOSTON-- ...

Lung01 Phase 2 trial, with support from IDeate-PanTumor01 Phase 1/2 trialIf approved, ifinatamab deruxtecan would be a first-in-class B7-H3 directed DXd antibody drug conjugate for these patients ...

WHAT: Southern Glazer's Wine & Spirits, the world's preeminent distributor of beverage alcohol, will be represented by Karli Sage, Vice President, Supply Chain Management, Technology & Engineering, as ...

K Additive, Inc. a leader in the domestic production of high-performance metal powders, welcomed Congressman Guy Reschenthaler (PA-14) to its Burgettstown facility. The visit underscored the critical ...

FDA has accepted and granted Priority Review to the biologics license application for ifinatamab deruxtecan in adults with ...